PortalPublikationenHigh prevalence of NMDA receptor IgA/IgM antibodies in diffe...

High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types

Standard

High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. / Doss, Sarah; Wandinger, Klaus-Peter; Hyman, Bradley T; Panzer, Jessica A; Synofzik, Matthis; Dickerson, Bradford; Mollenhauer, Brit; Scherzer, Clemens R; Ivinson, Adrian J; Finke, Carsten; Schöls, Ludger; Müller Vom Hagen, Jennifer; Trenkwalder, Claudia; Jahn, Holger; Höltje, Markus; Biswal, Bharat B; Harms, Lutz; Ruprecht, Klemens; Buchert, Ralph; Höglinger, Günther U; Oertel, Wolfgang H; Unger, Marcus M; Körtvélyessy, Peter; Bittner, Daniel; Priller, Josef; Spruth, Eike J; Paul, Friedemann; Meisel, Andreas; Lynch, David R; Dirnagl, Ulrich; Endres, Matthias; Teegen, Bianca; Probst, Christian; Komorowski, Lars; Stöcker, Winfried; Dalmau, Josep; Prüss, Harald.

in: ANN CLIN TRANSL NEUR, Jahrgang 1, Nr. 10, 01.10.2014, S. 822-832.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Doss, S, Wandinger, K-P, Hyman, BT, Panzer, JA, Synofzik, M, Dickerson, B, Mollenhauer, B, Scherzer, CR, Ivinson, AJ, Finke, C, Schöls, L, Müller Vom Hagen, J, Trenkwalder, C, Jahn, H, Höltje, M, Biswal, BB, Harms, L, Ruprecht, K, Buchert, R, Höglinger, GU, Oertel, WH, Unger, MM, Körtvélyessy, P, Bittner, D, Priller, J, Spruth, EJ, Paul, F, Meisel, A, Lynch, DR, Dirnagl, U, Endres, M, Teegen, B, Probst, C, Komorowski, L, Stöcker, W, Dalmau, J & Prüss, H 2014, 'High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types', ANN CLIN TRANSL NEUR, Jg. 1, Nr. 10, S. 822-832. https://doi.org/10.1002/acn3.120

APA

Doss, S., Wandinger, K-P., Hyman, B. T., Panzer, J. A., Synofzik, M., Dickerson, B., Mollenhauer, B., Scherzer, C. R., Ivinson, A. J., Finke, C., Schöls, L., Müller Vom Hagen, J., Trenkwalder, C., Jahn, H., Höltje, M., Biswal, B. B., Harms, L., Ruprecht, K., Buchert, R., ... Prüss, H. (2014). High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. ANN CLIN TRANSL NEUR, 1(10), 822-832. https://doi.org/10.1002/acn3.120

Vancouver

Doss S, Wandinger K-P, Hyman BT, Panzer JA, Synofzik M, Dickerson B et al. High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. ANN CLIN TRANSL NEUR. 2014 Okt 1;1(10):822-832. https://doi.org/10.1002/acn3.120

Bibtex

@article{f7dcc450257846179fcf93d47e9bc793,
title = "High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types",
abstract = "OBJECTIVE: To retrospectively determine the frequency of N-Methyl-D-Aspartate (NMDA) receptor (NMDAR) autoantibodies in patients with different forms of dementia.METHODS: Clinical characterization of 660 patients with dementia, neurodegenerative disease without dementia, other neurological disorders and age-matched healthy controls combined with retrospective analysis of serum or cerebrospinal fluid (CSF) for the presence of NMDAR antibodies. Antibody binding to receptor mutants and the effect of immunotherapy were determined in a subgroup of patients.RESULTS: Serum NMDAR antibodies of IgM, IgA, or IgG subtypes were detected in 16.1% of 286 dementia patients (9.5% IgM, 4.9% IgA, and 1.7% IgG) and in 2.8% of 217 cognitively healthy controls (1.9% IgM and 0.9% IgA). Antibodies were rarely found in CSF. The highest prevalence of serum antibodies was detected in patients with {"}unclassified dementia{"} followed by progressive supranuclear palsy, corticobasal syndrome, Parkinson's disease-related dementia, and primary progressive aphasia. Among the unclassified dementia group, 60% of 20 patients had NMDAR antibodies, accompanied by higher frequency of CSF abnormalities, and subacute or fluctuating disease progression. Immunotherapy in selected prospective cases resulted in clinical stabilization, loss of antibodies, and improvement of functional imaging parameters. Epitope mapping showed varied determinants in patients with NMDAR IgA-associated cognitive decline.INTERPRETATION: Serum IgA/IgM NMDAR antibodies occur in a significant number of patients with dementia. Whether these antibodies result from or contribute to the neurodegenerative disorder remains unknown, but our findings reveal a subgroup of patients with high antibody levels who can potentially benefit from immunotherapy.",
author = "Sarah Doss and Klaus-Peter Wandinger and Hyman, {Bradley T} and Panzer, {Jessica A} and Matthis Synofzik and Bradford Dickerson and Brit Mollenhauer and Scherzer, {Clemens R} and Ivinson, {Adrian J} and Carsten Finke and Ludger Sch{\"o}ls and {M{\"u}ller Vom Hagen}, Jennifer and Claudia Trenkwalder and Holger Jahn and Markus H{\"o}ltje and Biswal, {Bharat B} and Lutz Harms and Klemens Ruprecht and Ralph Buchert and H{\"o}glinger, {G{\"u}nther U} and Oertel, {Wolfgang H} and Unger, {Marcus M} and Peter K{\"o}rtv{\'e}lyessy and Daniel Bittner and Josef Priller and Spruth, {Eike J} and Friedemann Paul and Andreas Meisel and Lynch, {David R} and Ulrich Dirnagl and Matthias Endres and Bianca Teegen and Christian Probst and Lars Komorowski and Winfried St{\"o}cker and Josep Dalmau and Harald Pr{\"u}ss",
year = "2014",
month = oct,
day = "1",
doi = "10.1002/acn3.120",
language = "English",
volume = "1",
pages = "822--832",
journal = "ANN CLIN TRANSL NEUR",
issn = "2328-9503",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

RIS

TY - JOUR

T1 - High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types

AU - Doss, Sarah

AU - Wandinger, Klaus-Peter

AU - Hyman, Bradley T

AU - Panzer, Jessica A

AU - Synofzik, Matthis

AU - Dickerson, Bradford

AU - Mollenhauer, Brit

AU - Scherzer, Clemens R

AU - Ivinson, Adrian J

AU - Finke, Carsten

AU - Schöls, Ludger

AU - Müller Vom Hagen, Jennifer

AU - Trenkwalder, Claudia

AU - Jahn, Holger

AU - Höltje, Markus

AU - Biswal, Bharat B

AU - Harms, Lutz

AU - Ruprecht, Klemens

AU - Buchert, Ralph

AU - Höglinger, Günther U

AU - Oertel, Wolfgang H

AU - Unger, Marcus M

AU - Körtvélyessy, Peter

AU - Bittner, Daniel

AU - Priller, Josef

AU - Spruth, Eike J

AU - Paul, Friedemann

AU - Meisel, Andreas

AU - Lynch, David R

AU - Dirnagl, Ulrich

AU - Endres, Matthias

AU - Teegen, Bianca

AU - Probst, Christian

AU - Komorowski, Lars

AU - Stöcker, Winfried

AU - Dalmau, Josep

AU - Prüss, Harald

PY - 2014/10/1

Y1 - 2014/10/1

N2 - OBJECTIVE: To retrospectively determine the frequency of N-Methyl-D-Aspartate (NMDA) receptor (NMDAR) autoantibodies in patients with different forms of dementia.METHODS: Clinical characterization of 660 patients with dementia, neurodegenerative disease without dementia, other neurological disorders and age-matched healthy controls combined with retrospective analysis of serum or cerebrospinal fluid (CSF) for the presence of NMDAR antibodies. Antibody binding to receptor mutants and the effect of immunotherapy were determined in a subgroup of patients.RESULTS: Serum NMDAR antibodies of IgM, IgA, or IgG subtypes were detected in 16.1% of 286 dementia patients (9.5% IgM, 4.9% IgA, and 1.7% IgG) and in 2.8% of 217 cognitively healthy controls (1.9% IgM and 0.9% IgA). Antibodies were rarely found in CSF. The highest prevalence of serum antibodies was detected in patients with "unclassified dementia" followed by progressive supranuclear palsy, corticobasal syndrome, Parkinson's disease-related dementia, and primary progressive aphasia. Among the unclassified dementia group, 60% of 20 patients had NMDAR antibodies, accompanied by higher frequency of CSF abnormalities, and subacute or fluctuating disease progression. Immunotherapy in selected prospective cases resulted in clinical stabilization, loss of antibodies, and improvement of functional imaging parameters. Epitope mapping showed varied determinants in patients with NMDAR IgA-associated cognitive decline.INTERPRETATION: Serum IgA/IgM NMDAR antibodies occur in a significant number of patients with dementia. Whether these antibodies result from or contribute to the neurodegenerative disorder remains unknown, but our findings reveal a subgroup of patients with high antibody levels who can potentially benefit from immunotherapy.

AB - OBJECTIVE: To retrospectively determine the frequency of N-Methyl-D-Aspartate (NMDA) receptor (NMDAR) autoantibodies in patients with different forms of dementia.METHODS: Clinical characterization of 660 patients with dementia, neurodegenerative disease without dementia, other neurological disorders and age-matched healthy controls combined with retrospective analysis of serum or cerebrospinal fluid (CSF) for the presence of NMDAR antibodies. Antibody binding to receptor mutants and the effect of immunotherapy were determined in a subgroup of patients.RESULTS: Serum NMDAR antibodies of IgM, IgA, or IgG subtypes were detected in 16.1% of 286 dementia patients (9.5% IgM, 4.9% IgA, and 1.7% IgG) and in 2.8% of 217 cognitively healthy controls (1.9% IgM and 0.9% IgA). Antibodies were rarely found in CSF. The highest prevalence of serum antibodies was detected in patients with "unclassified dementia" followed by progressive supranuclear palsy, corticobasal syndrome, Parkinson's disease-related dementia, and primary progressive aphasia. Among the unclassified dementia group, 60% of 20 patients had NMDAR antibodies, accompanied by higher frequency of CSF abnormalities, and subacute or fluctuating disease progression. Immunotherapy in selected prospective cases resulted in clinical stabilization, loss of antibodies, and improvement of functional imaging parameters. Epitope mapping showed varied determinants in patients with NMDAR IgA-associated cognitive decline.INTERPRETATION: Serum IgA/IgM NMDAR antibodies occur in a significant number of patients with dementia. Whether these antibodies result from or contribute to the neurodegenerative disorder remains unknown, but our findings reveal a subgroup of patients with high antibody levels who can potentially benefit from immunotherapy.

U2 - 10.1002/acn3.120

DO - 10.1002/acn3.120

M3 - SCORING: Journal article

C2 - 25493273

VL - 1

SP - 822

EP - 832

JO - ANN CLIN TRANSL NEUR

JF - ANN CLIN TRANSL NEUR

SN - 2328-9503

IS - 10

ER -